Fig. 3: Substantial variability in time-on-treatment (TOT) with pembrolizumab and overall survival (OS) from start of pembrolizumab in TMB-High and MSI-High/MMRd tumors across cancer types.
From: Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals
Median pembrolizumab TOT (A, C, E) and OS (B, D, F) for patients with TMB-High tumors (A, B), MSI-High/MMRd tumors (C, D), or the MSS/MMRp subset of TMB-High tumors (E, F). Whiskers indicate 95% confidence intervals; when no endcap is shown, upper 95% CI is undefined. Dotted line indicates median TOT or OS across cancer types (i.e., global median of all patients in cohort). Black asterisks indicate cancer types with median TOT/OS significantly higher than global median and red asterisks indicate median TOT/OS lower than the global median. Shown are cancer types with n ≥ 40 patients (A, B), n ≥ 10 patients (C, D), and n ≥ 25 patients (E, F). ‘n’ for each tumor type and analysis is shown in parentheses on the y-axis. HRs were computed utilizing the Cox proportional hazards model, and P values were assessed by two-sided log-rank test (no multiple comparison testing). Full tables of all cancer types are shown in Supplementary Data S4–9.
